Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5094658
Max Phase: Preclinical
Molecular Formula: C52H75N11O9
Molecular Weight: 998.24
Molecule Type: Unknown
Associated Items:
ID: ALA5094658
Max Phase: Preclinical
Molecular Formula: C52H75N11O9
Molecular Weight: 998.24
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(N)=O)C(C)C
Standard InChI: InChI=1S/C52H75N11O9/c1-30(2)25-40(47(68)59-39(45(53)66)27-34-15-10-8-11-16-34)62-51(72)44(32(5)6)63-50(71)41(26-31(3)4)60-49(70)43(29-36-20-22-37(65)23-21-36)61-46(67)38(19-14-24-56-52(54)55)58-48(69)42(57-33(7)64)28-35-17-12-9-13-18-35/h8-13,15-18,20-23,30-32,38-44,65H,14,19,24-29H2,1-7H3,(H2,53,66)(H,57,64)(H,58,69)(H,59,68)(H,60,70)(H,61,67)(H,62,72)(H,63,71)(H4,54,55,56)/t38-,39-,40-,41-,42-,43-,44-/m0/s1
Standard InChI Key: WYTDWRNUHXAMTO-VLOLPVCOSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 998.24 | Molecular Weight (Monoisotopic): 997.5749 | AlogP: 1.33 | #Rotatable Bonds: 29 |
Polar Surface Area: 328.92 | Molecular Species: BASE | HBA: 10 | HBD: 12 |
#RO5 Violations: 2 | HBA (Lipinski): 20 | HBD (Lipinski): 14 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.50 | CX Basic pKa: 11.54 | CX LogP: 1.89 | CX LogD: 0.23 |
Aromatic Rings: 3 | Heavy Atoms: 72 | QED Weighted: 0.03 | Np Likeness Score: 0.09 |
1. Lior Y, Shtriker E, Kahremany S, Lewis EC, Gruzman A.. (2022) Development of anti-inflammatory peptidomimetics based on the structure of human alpha1-antitrypsin., 228 [PMID:34763945] [10.1016/j.ejmech.2021.113969] |
Source(1):